CORONAVIRUS (COVID-19) Notice for all patients and visitors.
We are a clinician-led organisation where patient education and support services are initiated by the very people who treat breast cancer patients every day.
Your donation will help us enhance breast cancer treatment and care, and increase survival rates.
We began in 2009 with a vision to provide high quality care while conducting research that would deliver the most advanced treatments and save lives.
BCRC-WA conducts research into breast cancer treatment and care that underpins the treatment we provide to our patients.
PBCI will help us continue to reshape the future of breast cancer – offering world class treatment, care and support to patients and their families.
In May, BCRC-WA welcomed the announcement that the Food and Drug Administration (the licencing body for new medications in the USA) had given approval for use of the drug Neratinib.
This is a drug used exclusively for patients with HER2-positive breast cancer. Neratinib, an oral drug, was evaluated in the ExteNET trial which commenced 8 years ago with the involvement of 497 cancer centres in 41 countries. We are proud to have been the world’s leading recruiter and successfully passed an FDA audit in the lead-up to the drug’s approval.
Listen to Professor Arlene Chan and Shereen Jolly discuss Neratinib on Ten Eye Witness News.